Bioinformatics-Based Discovery of CKLF-Like MARVEL Transmembrane Member 5 as a Novel Biomarker for Breast Cancer
暂无分享,去创建一个
San-Gang Wu | Jun Wang | Zhen-Yu He | L. Hua | Juan Zhou | J. Lei | Chen-Lu Lian
[1] Xiaoman Li,et al. Research Advances in CKLF-like MARVEL Transmembrane Domain-containing Family in Non-small Cell Lung Cancer , 2019, International journal of biological sciences.
[2] Yili Yang,et al. Overexpression of CMTM7 inhibits cell growth and migration in liver cancer , 2019, The Kaohsiung journal of medical sciences.
[3] P. Fasching,et al. Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus , 2019, Geburtshilfe und Frauenheilkunde.
[4] R. Lara-Lemus. On The Role of Myelin and Lymphocyte Protein (MAL) In Cancer: A Puzzle With Two Faces , 2019, Journal of Cancer.
[5] S. Hochwald,et al. Expression of tetraspanins NET-6 and CD151 in breast cancer as a potential tumor biomarker , 2019, Clinical and Experimental Medicine.
[6] J. Kong,et al. Expression and Clinical Significance of CMTM6 in Hepatocellular Carcinoma. , 2019, DNA and cell biology.
[7] Andrew J. Oler,et al. Co-Expression of VEGF and IL-6 Family Cytokines is Associated with Decreased Survival in HER2 Negative Breast Cancer Patients: Subtype-Specific IL-6 Family Cytokine-Mediated VEGF Secretion12 , 2018, Translational oncology.
[8] Shuo Li,et al. Up‐regulation of miR‐10b‐3p promotes the progression of hepatocellular carcinoma cells via targeting CMTM5 , 2018, Journal of cellular and molecular medicine.
[9] H. Woo,et al. Identification of genomic aberrations associated with lymph node metastasis in diffuse-type gastric cancer , 2018, Experimental & Molecular Medicine.
[10] G. Turashvili,et al. Tumor Heterogeneity in Breast Cancer , 2017, Front. Med..
[11] Shengkui Tan,et al. Clinical significance of CMTM4 expression in hepatocellular carcinoma , 2017, OncoTargets and therapy.
[12] L. H. Mendoza,et al. El cáncer de mama en el siglo XXI: de la detección precoz a los nuevos tratamientos , 2017 .
[13] J. Bonilla,et al. Breast cancer in the 21st century: From early detection to new therapies , 2017 .
[14] S. Dawson,et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity , 2017, Nature.
[15] Chad J. Creighton,et al. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses , 2017, Neoplasia.
[16] H. Horlings,et al. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators , 2017, Nature.
[17] Shao-bin Zheng,et al. CMTM5 inhibits renal cancer cell growth through inducing cell-cycle arrest and apoptosis , 2017, Oncology letters.
[18] A. Lánczky,et al. miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients , 2016, Breast Cancer Research and Treatment.
[19] B. Pang,et al. Cancer Research Advance in CKLF-like MARVEL Transmembrane Domain Containing Member Family (Review). , 2016, Asian Pacific journal of cancer prevention : APJCP.
[20] Kexin Xu,et al. Functional characterization of the tumor suppressor CMTM8 and its association with prognosis in bladder cancer , 2016, Tumor Biology.
[21] Shailesh Singh,et al. CXCR6-CXCL16 axis promotes prostate cancer by mediating cytoskeleton rearrangement via Ezrin activation and αvβ3 integrin clustering , 2016, Oncotarget.
[22] Qi-hua He,et al. CMTM7 knockdown increases tumorigenicity of human non-small cell lung cancer cells and EGFR-AKT signaling by reducing Rab5 activation , 2015, Oncotarget.
[23] Tao Xu,et al. CMTM4 is frequently downregulated and functions as a tumour suppressor in clear cell renal cell carcinoma , 2015, Journal of experimental & clinical cancer research : CR.
[24] Weidong Yu,et al. CMTM8 inhibits the carcinogenesis and progression of bladder cancer , 2015, Oncology reports.
[25] A. Koch,et al. MEXPRESS: visualizing expression, DNA methylation and clinical TCGA data , 2015, BMC Genomics.
[26] A. Bosserhoff,et al. Systematic investigation of CMTM family genes suggests relevance to glioblastoma pathogenesis and CMTM1 and CMTM3 as priority targets , 2015, Genes, chromosomes & cancer.
[27] X. Wang,et al. CMTM5 is reduced in prostate cancer and inhibits cancer cell growth in vitro and in vivo , 2015, Clinical and Translational Oncology.
[28] C. Mathers,et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.
[29] Hsien-Da Huang,et al. MethHC: a database of DNA methylation and gene expression in human cancer , 2014, Nucleic Acids Res..
[30] Davide Heller,et al. STRING v10: protein–protein interaction networks, integrated over the tree of life , 2014, Nucleic Acids Res..
[31] J. Morales-Montor,et al. The Role of Chemokines in Breast Cancer Pathology and Its Possible Use as Therapeutic Targets , 2014, Journal of immunology research.
[32] Heyu Zhang,et al. CMTM5 exhibits tumor suppressor activity through promoter methylation in oral squamous cell carcinoma. , 2014, Biochemical and biophysical research communications.
[33] H. Kalofonos,et al. Expression of claudins-1, -4, -5, -7 and occludin in hepatocellular carcinoma and their relation with classic clinicopathological features and patients' survival. , 2014, In vivo.
[34] J. Xie,et al. CMTM3 is frequently reduced in clear cell renal cell carcinoma and exhibits tumor suppressor activities , 2014, Clinical and Translational Oncology.
[35] Jun Wang,et al. Change of CMTM7 expression, a potential tumor suppressor, is associated with poor clinical outcome in human non‐small cell lung cancer , 2013, Chinese medical journal.
[36] D. Taub,et al. Differential G protein subunit expression by prostate cancer cells and their interaction with CXCR5 , 2013, Molecular Cancer.
[37] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[38] Robin L. Anderson,et al. Oncostatin m promotes mammary tumor metastasis to bone and osteolytic bone degradation. , 2012, Genes & cancer.
[39] Stephanie Alexander,et al. Cancer Invasion and the Microenvironment: Plasticity and Reciprocity , 2011, Cell.
[40] John S. Condeelis,et al. Chemotaxis in cancer , 2011, Nature Reviews Cancer.
[41] Shailesh Singh,et al. Chemokines: key players in cancer progression and metastasis. , 2011, Frontiers in bioscience.
[42] B. Kong,et al. Reduced CMTM5 Expression Correlates With Carcinogenesis in Human Epithelial Ovarian Cancer , 2011, International Journal of Gynecologic Cancer.
[43] J. Scheller,et al. The pro- and anti-inflammatory properties of the cytokine interleukin-6. , 2011, Biochimica et biophysica acta.
[44] G. Getz,et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.
[45] Antoine M. van Oijen,et al. Real-time single-molecule observation of rolling-circle DNA replication , 2009, Nucleic acids research.
[46] Brad T. Sherman,et al. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.
[47] Jun Wang,et al. Expression of CKLF1,CMTM1,CMTM2 and CMTM4 in non-small cell lung cancer , 2008 .
[48] Q. Tao,et al. CMTM5 Exhibits Tumor Suppressor Activities and Is Frequently Silenced by Methylation in Carcinoma Cell Lines , 2007, Clinical Cancer Research.
[49] J. Condeelis,et al. Regulation of the actin cytoskeleton in cancer cell migration and invasion. , 2007, Biochimica et biophysica acta.
[50] Jae Hoon Kim,et al. Analysis of chromosomal changes in serous ovarian carcinoma using high‐resolution array comparative genomic hybridization: Potential predictive markers of chemoresistant disease , 2007, Genes, chromosomes & cancer.
[51] J. Scheller,et al. Updating interleukin-6 classic- and trans-signaling , 2006 .
[52] Francis Lin,et al. Differential effects of EGF gradient profiles on MDA-MB-231 breast cancer cell chemotaxis. , 2004, Experimental cell research.
[53] C. Jorcyk,et al. Oncostatin M induces cell detachment and enhances the metastatic capacity of T-47D human breast carcinoma cells. , 2004, Cytokine.
[54] Yingyu Chen,et al. Identification of eight genes encoding chemokine-like factor superfamily members 1-8 (CKLFSF1-8) by in silico cloning and experimental validation. , 2003, Genomics.
[55] A. Ben-Baruch,et al. Host microenvironment in breast cancer development: Inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor–microenvironment interactions , 2002, Breast Cancer Research.
[56] L. Ellis,et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis , 2002, Oncogene.
[57] Shengkui Tan,et al. Clinical significance of CMTM 4 expression in hepatocellular carcinoma , 2017 .
[58] J. Merino Bonilla,et al. Breast cancer in the 21st century: from early detection to new therapies. , 2017, Radiologia.
[59] B. Pang,et al. Advances Regarding the CKLF-like MARVEL Transmembrane Domain Containing Family , 2016 .
[60] W. Coleman,et al. Enhancement of chemotherapeutic efficacy in hypermethylator breast cancer cells through targeted and pharmacologic inhibition of DNMT3b , 2011, Breast Cancer Research and Treatment.
[61] Brad T. Sherman,et al. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.
[62] T. Barrette,et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.